

Patent
030639.0053.CPA1IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Young et al.

Serial No.: 08/851,965

Filed: March 12, 2001

Title: METHOD FOR PREVENTING
GASTRITIS USING AMYLIN OR
AMYLIN AGONISTS

Group Art Unit: 1627

Examiner: Celsa, B.

#261
M.M.
10/2/01Commissioner for Patents
Washington, D.C. 20231**AMENDMENT**

Dear Sir:

This Communication is responsive to the Office Action mailed June 19, 2001, and is being timely filed with a Petition for a One-Month Extension of Time. Applicants request that the Examiner enter the following amendments and consider the following remarks.

In the Specification

Please replace the paragraph on page 5, lines 19-30 with the following:

D1 --In fat cells, contrary to its action in muscle, amylin has no detectable actions on insulin-stimulated glucose uptake, incorporation of glucose into triglyceride, CO₂ production (Cooper et al., *Proc. Natl. Acad. Sci.*, 85:7763-7766 (1988)), epinephrine-stimulated lipolysis, or insulin-inhibition of lipolysis (Lupien and Young, "Diabetes Nutrition and Metabolism - Clinical and Experimental," Vol. 6(1), pages 1318 (February 1993)). Amylin thus exerts tissue-specific effects, with direct action on skeletal muscle, and indirect (via supply of substrate) effects on liver, while adipocytes appear "blind" to the presence or absence of amylin.--

Please replace the paragraphs on page 6, line 1, through page 7, line 13, with the following:

CERTIFICATE OF MAILING
(37 C.F.R. §1.8)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being transmitted, via facsimile, to the United States Patent and Trademark Office on September 25, 2001.

Lisa M. McGeehan
Lisa M. McGeehan